Business
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today provided an update on its ongoing clinical trial in patients with T1D. Yesterday, on March 31, the Data and S
About this update from Sernova Biotherapeutics Inc
[{"type":"image","alt":"Sernova Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Sernova Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/a1e27d29b817b2345a46d198e0ed572e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ihDMger9siI_3NadL4eNFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a1e27d29b817b2345a46d198e0ed572e","width":300,"height":56}},"lazy":false},{"type":"text","content":"DSMB supports advancement for Sernova’s clinical trial","length":54,"tagName":"p"},{"type":"text","content":"Study is on track to meet key clinical trial endpoints","length":54,"tagName":"p"},{"type":"text","content":"LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today provided an update on its ongoing clinical trial in patients with T1D.","length":351,"tagName":"p"},{"type":"text","content":"Yesterday, on March 31, the Data and Safety Management Board (DSMB) for Sernova’s Phase 1/2 clinical trial, conducted a scheduled annual data review. The DSMB has sanctioned the enrollment of the final patient in Cohort B. In addition, following consultation with the DSMB, Sernova is preparing to advance to Cohort C of the trial in H2 2025.","length":342,"tagName":"p"},{"type":"text","content":"The primary endpoint of our ongoing Phase 1/2 clinical trial is the demonstration of safety and tolerability of islet transplantation into Cell Pouch for the treatment of T1D in patients with hypoglycemia unawareness and a history of severe hypoglycemic episodes. Based on the clinical data that Sernova has acquired to date, and the endorsement of safety from the DSMB, we believe we are on track to achieve this endpoint.","length":423,"tagName":"p"},{"type":"text","content":"Upon conclusion of Cohort C, Sernova plans to launch a T1D clinical trial of the Cell Pouch™ Bio-hybrid Organ with induced pluripotent stem cell (iPSC) islet-like clusters in collaboration with Evotec.","length":201,"tagName":"p"},{"type":"text","content":"We believe that Sernova’s Cell Pouch™ Bio-hybrid Organ, that is...